COMMUNIQUÉS West-GlobeNewswire

Cingulate Names Industry Veteran Bryan Downey Chief Commercial Officer to Lead Launch Preparation for CTx-1301
10/11/2025
Appointment builds on recent FDA acceptance of New Drug Application for review and advances Cingulate’s transition toward commercialization pending FDA approval Company also strengthens its cash position by completing a [...]
SRx Health Solutions Appoints Sammy Dorf to Board of Directors
10/11/2025
TAMPA, Fla., Nov. 10, 2025 (GLOBE NEWSWIRE) -- SRx Health Solutions, Inc. (NYSE American: SRXH) (the “Company”) today announced the appointment of Sammy Dorf, Esq. to its Board of Directors. Sammy is a pioneering force [...]
4DMT Reports Third Quarter 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones
10/11/2025
Entered strategic partnership with Otsuka Pharmaceutical Co., Ltd. for the development and commercialization of 4D-150 in the APAC region; to receive $85 million in upfront cash and expects to receive at least $50 [...]
SpyGlass Pharma Announces Positive 36-Month First-in-Human and 3-Month Phase I/II Trial Results for Its Novel BIM-IOL System
10/11/2025
First-in-Human (FIH) Trial at 36 Months : 37% reduction in mean intraocular pressure (IOP) in evaluable patients across all dose groups with 95% of patients off all topical IOP-lowering drops 100% of evaluable patients [...]
Vaxxas Appoints Veteran Vaccine Leader to Board as Company Advances Needle-Free Vaccine Patch Towards Market
10/11/2025
Seasoned global pharmaceutical executive, Mr Brent MacGregor, joins Vaxxas Board to accelerate self-administered HD-MAP vaccines for global use; SPRIM Global Investment’s Co-Founder and Managing Partner, Mr Michael [...]
Humacyte Announces Presentation of Positive Two-Year Results from Phase 3 Dialysis Access Trial at the American Society of Nephrology’s Kidney Week 2025
10/11/2025
– The ATEV™ was observed to have superior duration of use over 24 months compared to autogenous fistula in high-need subgroups with historically poor outcomes with AV fistula procedures – – The significantly longer [...]
ITM to Participate in Upcoming Investor Conferences
10/11/2025
Garching / Munich, Germany, November 10, 2025 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced its participation in upcoming industry investor conferences and [...]
UK High Court Rules in Favor of Alvotech Paving Way for Manufacture and Market Entry of AVT06, biosimilar to Eylea® (aflibercept)
10/11/2025
REYKJAVIK, Iceland, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today the [...]
UK High Court Rules in Favor of Alvotech Paving Way for Manufacture and Market Entry of AVT06, biosimilar to Eylea® (aflibercept)
10/11/2025
REYKJAVIK, ICELAND (November 10, 2025) — Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today the outcome of [...]
GENFIT Enters Research Collaboration with EVerZom to Advance Exosome-based Regenerative Technology in ACLF
10/11/2025
EVerZom’s investigational drug candidate EViv, developed to treat ACLF, using its proprietary exosome platform, represents a novel approach to regenerative therapies Pending successful in vivo proof-of-concept results, [...]
GENFIT signe un partenariat de recherche avec EVerZom pour faire progresser une technologie de médecine régénérative basée sur les exosomes dans l’ACLF
10/11/2025
Le candidat-médicament expérimental EViv d'EVerZom, développé pour le traitement de l'ACLF en utilisant sa plateforme propriétaire d'exosomes, représente une approche novatrice en matière de thérapies régénératives En [...]
GENFIT Presents Promising New Preclinical Data on NTZ/G1090N for the Treatment of ACLF at The Liver Meeting® 2025
10/11/2025
Preclinical studies demonstrated significant efficacy on systemic inflammation and organ function in ACLF disease models Safety data from Phase 1 on healthy volunteers and initial efficacy signals from ex-vivo [...]
GENFIT présente de nouvelles données précliniques prometteuses sur NTZ/G1090N dans le traitement de l’ACLF dans le cadre du Liver Meeting® 2025
10/11/2025
Des études précliniques ont démontré une efficacité significative sur l'inflammation systémique et le fonctionnement des organes dans des modèles pathologiques d'ACLF. Des données de sécurité issues de l’étude de Phase [...]
[Ad hoc announcement pursuant to Art. 53 LR] Roche’s fenebrutinib shows unprecedented positive Phase III results as the potential first and only BTK inhibitor in both relapsing and primary progressive multiple sclerosis
10/11/2025
The first (FENhance 2) of two pivotal RMS studies met its primary endpoint, showing investigational fenebrutinib significantly reduced relapses compared to teriflunomide In a pivotal PPMS study (FENtrepid), fenebrutinib [...]
BioVersys BV100 Phase 2b to be Conducted Via Wellcome Funded Trial Network
10/11/2025
TRIAL TO BE CONDUCTED BY ADVANCE-ID, A NATIONAL UNIVERSITY OF SINGAPORE LED TRIAL NETWORK, IN PARTNERSHIP WITH BIOVERSYS Ad hoc announcement pursuant to Art. 53 LR BASEL, Switzerland, Nov. 10, 2025 (GLOBE NEWSWIRE) -- [...]
AVITA Medical to Host Investor Webinar Briefing
09/11/2025
VALENCIA, Calif., Nov. 09, 2025 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (ASX: AVH, NASDAQ: RCEL), a leading therapeutic acute wound care company delivering transformative solutions, invites shareholders and prospective [...]
New REDUCE-IT® Aspirin Analysis Presented at AHA Scientific Sessions 2025 Reinforces VASCEPA®/VAZKEPA® (Icosapent Ethyl) Reduced Cardiovascular Events in High-Risk Patients
09/11/2025
DUBLIN and BRIDGEWATER, N.J., Nov. 09, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN), a company committed to advancing the science of cardiovascular care, today highlighted a new post hoc analysis of [...]
RadNet Reports Third Quarter Financial Results with Record Quarterly Revenue and Adjusted EBITDA¹ and Revises Upwards 2025 Financial Guidance Ranges
09/11/2025
Total Company Revenue increased 13.4% to $522.9 million in the third quarter of 2025 from $461.1 million in the third quarter of 2024; Revenue from the Digital Health reportable segment (inclusive of intersegment [...]
AHA 2025: Late-Breaking Data Reinforce the Prognostic Power of AI-Driven Heartflow Plaque Analysis as the Most Clinically Validated Framework for Coronary Risk Stratification
09/11/2025
Multicenter outcomes FISH&CHIPS study of nearly 8,000 patients confirms total plaque volume as a powerful independent predictor of long-term cardiovascular events NEW ORLEANS, Nov. 09, 2025 (GLOBE NEWSWIRE) -- [...]

Pages